Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for ...

and is also exploring use of the drug in combination with current therapies including pegylated interferon (PegIFN) and its experimental immunotherapies. GSK licensed the drug from longstanding ...

and expanded the agreement last year to include Chinese rights to the ADC as well as a pegylated formulation of interleukin-2 codenamed SAR444245. In a new pharmaphorum podcast, web editor Nicole ...

Jai Corp Limited has received Rs. 362.72 crore net of tax deducted at source from Urban Infrastructure Private Limited today ...

The Board of Directors of Adani Ports and Special Economic Zone Ltd. has approved the acquisition of Abbot Point Port ...

The management of chronic hepatitis B (CHB) during pregnancy remains a challenge and involves various aspects of maternal-fetal care. Despite the standard immunoprophylaxis, a significant portion ...